Functional protective agent for organ or tissue
A 2,5-diketopiperazine compound is used to protect and improve kidney and liver function in diseases like renal failure and diabetes, offering a safe and effective solution by ingestion as a pharmaceutical or food additive, effectively addressing the limitations of current treatments.
Patent Information
- Application Number
- PCT/JP2024/019139
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for kidney diseases, particularly diabetic nephropathy, are ineffective in preventing or reversing functional decline, often leading to renal failure, and existing agents may not be safe for ingestion.
A specific 2,5-diketopiperazine compound, represented by formula (I) and its physiologically acceptable salts, is used as a preventive or ameliorating agent to protect organ function, particularly for the kidneys and liver, by ingesting it as a pharmaceutical, pet feed, or food/drinks, which is safe for consumption.
The compound effectively reduces the decline in organ function caused by renal failure and diabetes, improving kidney and liver function, and reducing the risk of disease aggravation, as demonstrated by significant statistical differences in uremic substance concentrations and tissue analysis.
Smart Images

Figure JP2024019139_05122024_PF_FP_ABST
Abstract
Description
Organ or tissue function protectors
[0001] The present invention relates to an agent for preventing or ameliorating the decline in function of an organ or tissue (hereinafter, sometimes referred to as "organ, etc."), which contains a specific 2,5-diketopiperazine or a derivative thereof (hereinafter, sometimes referred to as "the present diketopiperazine compound") as an active ingredient.
[0002] The kidney is an extremely important organ that maintains homeostasis by regulating the concentrations of body fluid components through excretion and reabsorption, and also functions as an endocrine organ, producing and secreting physiologically active substances such as activated vitamin D, erythropoietin, and renin. Impairment or decline in kidney function, which plays such an important role, can lead to a variety of pathological conditions and result in a wide range of renal diseases. These kidney diseases include nephropathies closely related to diabetes, obesity, and dyslipidemia. Diabetic nephropathy, which is caused by diabetes as the underlying disease, is particularly difficult to prevent from progressing even with strict diabetes control after diagnosis, and many cases develop renal failure, resulting in a considerable number of patients.
[0003] 2,5-Diketopiperazines (also referred to as "cyclic dipeptides") are dipeptides having a cyclic structure formed by dehydration condensation of an amino group and a carboxyl group present at the terminus of a linear dipeptide, and have recently attracted attention for their various physiological activities. For example, it has been reported that certain diketopiperazines have the effect of improving the moisturizing function of the skin (Patent Document 1), the effect of activating or inhibiting the activity of the sympathetic nerves of the skin (Patent Document 2), and the effect of dilating blood vessels (Patent Document 3). However, it has not been known until now that 2,5-diketopiperazines are effective against the decline in organ function, etc.
[0004] International Publication No. 2016 / 063901 Pamphlet Japanese Patent Application Laid-Open No. 2022-48337 Japanese Patent Application Laid-Open No. 2018-16612
[0005] An object of the present invention is to provide a low molecular weight compound that is highly safe when ingested and has the effect of preventing or ameliorating the decline in organ function, etc.
[0006] The present inventors have been conducting intensive research to solve the above-mentioned problems, and in the course of this research, have found that a specific 2,5-diketopiperazine has the effect of improving the decline in organ function caused by diseases such as renal failure and diabetes, and have thus completed the present invention.
[0007] That is, the present invention is as follows: [1] An agent for preventing or ameliorating decreased function of an organ or tissue, comprising one or more compounds selected from the group consisting of compounds represented by the following formula (I) and physiologically acceptable salts thereof:
[0008]
[0009] In formula (I), R 1 and R 2 each independently represents H or a C1 to C6 alkyl group, R 3 and R 4 are each independently H; or a hydroxy group, a phenyl group, a hydroxyphenyl group, or S—CH 3 Group, NH 2 represents a C1-C6 alkyl group which may have at least one group selected from the group consisting of a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group; R 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, and R 2 and R 4 may form a ring via a C2-C4 alkylene group optionally having a hydroxy group. [2] The preventive or ameliorating agent according to the above-mentioned [1], wherein the compound represented by formula (I) is a compound represented by the following formula (I-1):
[0010] [3] The prophylactic or ameliorating agent according to [1] or [2] above, wherein the organ is the kidney or the liver. [4] The prophylactic or ameliorating agent according to any of [1] to [3] above, which is used to prevent or ameliorate the decline in organ or tissue function in a mammal suffering from renal failure or diabetes. [5] The prophylactic or ameliorating agent according to any of [1] to [4] above, which is in the form of a medicine, pet feed, or food or drink.
[0011] Other embodiments of the present invention include: a method for preventing or ameliorating (treating) organ dysfunction, comprising the step of administering the diketopiperazine compound to a mammal in need of such prevention or amelioration (treatment); the diketopiperazine compound for use in preventing or ameliorating (treating) organ dysfunction; and use of the diketopiperazine compound for producing an agent for preventing or ameliorating (treating) organ dysfunction.
[0012] The diketopiperazine compound has the effect of improving the decline in organ function caused by diseases such as renal failure and diabetes. Furthermore, since the diketopiperazine compound contains 2,5-diketopiperazines derived from food, it is highly safe when ingested. Therefore, ingesting the diketopiperazine compound can protect organ function, prevent and treat diseases such as renal failure and diabetes, and reduce the risk of these diseases becoming severe.
[0013] 2A and 2B show the results of measuring the concentration of a uremic substance (creatinine) (mean ± standard deviation) in plasma samples taken two weeks after feeding from three groups (a normal-fed group ["Control" in the figure], an adenine-fed control group ["RF" in the figure], and an adenine-fed cGP group ["RF-c(GP)" in the figure]) in Example 1. The symbols "*" and "**" in the figure indicate statistically significant differences (p<0.05 and p<0.01), respectively, based on Dunnett's test. These figures also show the results of analyzing kidney tissue from the three groups after two weeks of feeding in Example 1. FIG. 2A shows the results of analyzing the proportion (%) of renal tubules in the renal cortex (mean ± standard deviation). The symbol "**" in the figure indicates statistically significant differences (p<0.01) based on Dunnett's test. FIG. 2B shows a representative example of a histological image of the kidney tissue used in the analysis of FIG. 2A. Darker areas indicate normal renal parenchyma, and lighter areas indicate fibrotic regions. In Example 1, the ALT (alanine aminotransferase) concentration (FIG. 3A) and total cholesterol concentration (FIG. 3B) were measured in plasma samples taken two weeks after feeding from three groups (a normal-fed group ["Ctrl" in the figure], an adenine-fed control group ["RF" in the figure], and an adenine-fed cGP group ["RF-c(GP)" in the figure]). These figures show the results (mean ± standard deviation). An "*" in the figure indicates a statistically significant difference (p<0.05) based on Dunnett's test. In Example 2, the liver tissues of two groups (a normal-fed diabetic model group ["dbdb" in the figure] and a diabetic model cGP group ["dbdb-c(GP)" in the figure]) after six weeks of feeding were analyzed using hematoxylin-eosin staining (HE). The white spots in the tissue are lipid droplets. FIG. 1 shows the results of measuring creatinine concentrations in plasma samples 6 weeks after feeding from four groups (a wild-type normally fed group ["Normal" in the figure], a wild-type cGP group ["Normal-c(GP)" in the figure], a diabetic model normally fed group ["dbdb" in the figure], and a diabetic model cGP group ["dbdb-c(GP)" in the figure]) in Example 2.In the figure, "*", "**", and "***" indicate statistically significant differences (p<0.05, p<0.01, and p<0.001), respectively, by Dunnett's test. This figure shows the results of measuring the concentrations of three substances (creatinine [Figure 6A], phenyl sulfate [Figure 6B], and Ac6Lys [Figure 6C]) in the "plasma sample at week 0 after feeding" ("0w" in the figure) and the "plasma sample at week 6 after feeding" ("6w" in the figure) of the diabetic model cGP group in Example 2. The "*" in the figure indicates a statistically significant difference (p<0.05) by paired t-test. 7A and 7B show the results of measuring the concentrations of two uremic substances (1-methyladenosine [mIA] [FIG. 7A] and trimethylamine-N-oxide [TMAO] [FIG. 7B]) in plasma samples from two groups (a normally fed diabetes model group ["dbdb" in the figure] and a cGP diabetes model group ["dbdb-c(GP)" in the figure]) after five weeks of feeding in Example 3. "**" in the figure indicates a statistically significant difference (p<0.01) by unpaired t-test.
[0014] The preventive or ameliorating agent of the present invention comprises the present diketopiperazine compound, i.e., one or more compounds selected from the compound of the following formula (I) and physiologically acceptable salts thereof, and is an agent specified for the use "to prevent or ameliorate functional decline of an organ or tissue" (hereinafter, may be referred to as the "present preventive / ameliorating agent").
[0015]
[0016] In formula (I), R 1 and R 2 each independently represents H or a C1 to C6 alkyl group, R 3 and R 4 are each independently H; or a hydroxy group, a phenyl group, a hydroxyphenyl group, or S—CH 3 Group, NH 2a C1-C6 alkyl group (i.e., a C1-C6 alkyl group; or a hydroxy group, a phenyl group, a hydroxyphenyl group, an S—CH 3 Group, NH 2 a C1-C6 alkyl group having at least one group selected from the group consisting of a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group; R 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, R 2 and R 4 may form a ring via a C2-C4 alkylene group which may have a hydroxy group.
[0017] In formula (I), R 1 ~R 4 C1 to C6 alkyl groups such as R 2 Examples of the C1 to C6 alkyl group include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an s-butyl group, an i-butyl group, a t-butyl group, an n-pentyl group, and an n-hexyl group.
[0018] In formula (I), R 3 and R 4 The N-containing heteroaryl group, which is one of the substituents of the C1-C6 alkyl group, includes a 5- to 7-membered monocyclic or polycyclic aromatic heterocycle having 1 to 4 nitrogen atoms as heteroatoms, and a fused ring formed by condensing a benzene ring with a 5- to 7-membered heterocycle having 1 to 4 nitrogen atoms as heteroatoms. Examples thereof include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, pyrrolyl, quinolinyl, indolyl, benzimidazolyl, pyridazinyl, triazinyl, etc.
[0019] The diketopiperazine compound of the present invention includes stereoisomers (enantiomers, etc.), isomers such as tautomers, solvates, hydrates, etc., and mixtures thereof.
[0020] Physiologically acceptable salts of the compound represented by formula (I) include, for example, inorganic salts such as sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, and fluoride; acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, fumarate, maleate, benzoate, chlorobenzoate, methyl Examples of the salt include organic salts such as benzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, and tartrate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and ammonium salt.
[0021] Specific examples of the diketopiperazine compound of the present invention include the compound represented by the following formula (I-1) (cGP [cyclo-glycyl-proline]), the compound represented by the formula (I-2) (cGS [cyclo-glycyl-serine], the compound represented by the formula (I-3) (cGL [cyclo-glycyl-leucine]), the compound represented by the formula (I-4) (cGE [cyclo-glycyl-glutamic acid]), the compound represented by the formula (I-5) (cGA [cyclo-glycyl-alanine]), and the compound represented by the formula (I-6) (cGF [cyclo-glycyl-phenylalanine]). The compound represented by the following formula (I-1) is preferred because its effects have been demonstrated in the Examples described below.
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028] The diketopiperazine compound of the present invention may be a commercially available product, or may be synthesized by a known method.
[0029] Examples of a method for synthesizing the present diketopiperazine compound by a known production method include a method described in JP-A-2003-531197, in which a dipeptide represented by the following formula (II) is heated in an organic solvent while removing water by distillation.
[0030]
[0031] In formula (II), R 1 ~R 4 are R in formula (I), respectively. 1 ~R 4 It has the meaning of
[0032] The organic solvent may be any solvent that forms a low-boiling azeotrope with water, and examples thereof include acetonitrile, allyl alcohol, benzene, benzyl alcohol, n-butanol, 2-butanol, t-butanol, butyl acetate, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethyl acetal, dimethyl acetal, ethyl acetate, heptane, methyl isobutyl ketone, 3-pentanol, toluene, and xylene.
[0033] The reaction temperature is usually 50 to 200° C., preferably 80 to 150° C. The pH at which the cyclization is carried out is usually 2 to 9, preferably 3 to 7.
[0034] The dipeptide represented by formula (II) can be obtained, for example, by a dehydration condensation reaction between glycine and another amino acid or a derivative thereof.
[0035] Alternatively, it can be produced by heating an aqueous solution containing a linear dipeptide or a linear tripeptide at 70 to 100° C. under a pressure of 0.5 MPa or less, according to the method described in Japanese Patent No. 5,456,876.
[0036] 2,5-Diketopiperazine is known to be found in fruits and processed foods involving fermentation or cooking, such as black currants, cordyceps, cheese, braised beef, and chicken essence, and can be obtained as part of extracts or concentrates from foods.
[0037] As used herein, mammals include humans and non-human mammals (e.g., monkeys; mice; rats; pets such as dogs and cats; livestock such as rabbits, pigs, horses, cows, sheep, goats, and deer).
[0038] When the present preventive / ameliorating agent is ingested by or administered to a non-human mammal, the present diketopiperazine compound may be used alone as feed for the non-human mammal, or may be further mixed with additives and used in the form of a composition (i.e., a feed composition for the non-human mammal). When the present preventive / ameliorating agent is ingested by or administered to a non-human mammal or a human, the present diketopiperazine compound may be used alone as a food or beverage product or a pharmaceutical product (preparation), or may be further mixed with additives and used in the form of a composition (a food or beverage composition or a pharmaceutical composition). Examples of the above-mentioned food or beverage product include health foods (functional foods, nutritional supplements, health supplements, nutrient-enhanced foods, nutritionally regulated foods, supplements, etc.), health-promoting foods (foods for specified health uses, foods with nutrient functions, foods with functional claims, etc.), and herbal medicines. The present preventive / ameliorating agent is preferably a pharmaceutical product, pet feed, or a food or beverage product.
[0039] In this specification, examples of "organ or tissue" include the large intestine (colon or rectum), stomach, liver, heart, brain, spinal cord, lung, esophagus, duodenum, small intestine, skin, prostate, bladder, uterus, kidney, pancreas, spleen, trachea, bronchi, gallbladder, bile duct, bone, gums, adrenal gland, thyroid gland, blood vessels, etc., and kidney and liver are preferred examples because their effects have been demonstrated in the Examples described below.
[0040] As used herein, the term "decreased function of an organ or tissue" refers to a state in which the function of an organ or tissue is lower than normal due to a disease or the like, such as test values obtained through a health checkup (for example, blood concentrations of uremic substances [e.g., creatinine, phenyl sulfate, 1-methyladenosine, trimethylamine-N-oxide [TMAO; trimethylamine-N-oxide], indoxyl sulfate, urea nitrogen [BUN]], blood concentrations of factors that lead to renal failure in type 1 diabetes patients [e.g., Ac6Lys], estimated glomerular filtration rate [eGFR], tannins, etc.). This refers to a state in which the urinary protein concentration, blood concentration of liver function markers [e.g., AST [aspartate aminotransferase], ALT, ALP [alkaline phosphatase], γGTP, etc.], or blood concentration of lipids [e.g., triglycerides [TG], total cholesterol]] show abnormalities (e.g., a state in which the blood concentration of uremic substances is elevated, the blood concentration of factors that lead to renal failure in type 1 diabetes patients is elevated, eGFR is reduced, the urinary protein concentration [positive proteinuria], the blood concentration of liver function markers is elevated, the blood concentration of lipids is elevated, etc.). Examples of the above diseases include digestive system disorders such as stomatitis and enteritis; nervous system disorders such as polyneuritis and (developmental) coordination disorder; circulatory system disorders such as arteriosclerosis, anemia, erythropoietic disorders, hypertension, ischemic heart disease, pericarditis, myocarditis, (blood) coagulation disorders, heart failure, and cardiovascular disorders; skin disorders (diseases) such as pigmentation, pruritus, psoriasis, atopy, and alopecia; albuminuria, renal failure (acute renal failure or chronic renal failure), and acute urinary Examples of renal dysfunction include tubular necrosis, renal anemia, tubulointerstitial damage, acute nephritis, chronic nephritis, nephrosis, diabetic nephropathy, arteriosclerotic nephropathy, renal osteopathies (e.g., renal osteodystrophy), and overflow; dyslipidemia (hyperlipidemia); diabetes; stroke; myocardial infarction; cancer; autism; immunodeficiency; osteopathies; hyperparathyroidism; insulin resistance; malnutrition; inflammation (e.g., chronic inflammation); cell damage; and tremors.The above diseases also include symptoms or diseases involving lipopolysaccharide (LPS), such as IgA nephropathy, polycystic kidney disease, liver dysfunction (e.g., fulminant hepatitis, fatty liver, NASH, NAFLD), and cancer (e.g., bile carcinogenesis); inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; arteriosclerosis-related diseases; autoimmune diseases such as lupus, scleroderma, and rheumatoid arthritis; autism; Parkinson's disease; Alzheimer's disease; and sarcopenia. As used herein, the term "uremic substances" refers to substances (waste products, toxins, etc.) excreted by normal kidneys that increase (accumulate) in the blood when excretory function is impaired due to some cause, such as impaired renal function.
[0041] The subject for intake (administration) of the present preventive / ameliorating agent is not particularly limited as long as it is a mammal, and typically is a mammal in need of prevention or amelioration (treatment) of impaired organ function, etc., more specifically, a mammal in a state of impaired organ or tissue function caused by the above-mentioned diseases, etc., and since its effectiveness has been demonstrated in the Examples described below, mammals suffering from renal failure or diabetes are suitable examples. Ingestion of the present diketopiperazine compound contained in the present preventive / ameliorating agent improves test values obtained in health checkups, protects organ or tissue function, and contributes to the prevention or treatment of the above-mentioned diseases as well as reducing the risk of aggravation. Therefore, the present preventive / ameliorating agent can be used for improving test values obtained in health checkups; protecting organ or tissue function; preventing or treating the above-mentioned diseases; or reducing the risk of aggravation of the above-mentioned diseases.
[0042] The administration form of the present preventive / ameliorating agent can be exemplified by oral administration in the form of powder, granules, tablets, capsules, syrup, jelly, gum, troches, gummies, film, etc., or parenteral administration in the form of topical skin preparations, transdermal preparations, transmucosal preparations, nasal preparations, enteral preparations, injections, suppositories, inhalants, patches, etc. Such parenteral administration includes administration via a gastrostomy or other fistula in the form of a liquid, semisolid, etc., or via tube feeding using a nasogastric tube.
[0043] The present preventive / ameliorating agent for oral ingestion (administration) can be a sustained-release agent or an enteric-coated agent. Such enteric-coated agents can be obtained, for example, by filling granules containing the present diketopiperazine compound as an active ingredient with an enteric coating (i.e., a coating mainly composed of a base [enteric ingredient] that is resistant to gastric juice and dissolves in the small intestine), or by adding a lubricant to granules containing the present diketopiperazine compound as an active ingredient, compressing the resulting tablets, and coating the tablets with an enteric coating.
[0044] Examples of methods for obtaining the present preventive / ameliorative agent in tablet form include a method of mixing the present diketopiperazine compound, which is the active ingredient, with any ingredients (additives) that can be added as needed, and then compressing and molding the mixture to obtain tablets, and a method of further coating the tablets obtained after compression and molding with an enteric ingredient (enteric-coated method), and the latter method is preferred.
[0045] Examples of the enteric ingredient include shellac, zein, hydroxymethylcellulose phthalate, carboxymethylcellulose, carboxymethylethylcellulose, cellulose acetate phthalate, methacrylic acid copolymer, water-insoluble ethylcellulose, aminoalkyl methacrylate copolymer, brewer's yeast cell wall (for example, product name Yeasttrap, etc.), tapioca starch, gelatin, pectin, etc., among which shellac is preferred. Whether or not a substance is an enteric agent can be confirmed by the disintegration test method of the 14th edition of the Japanese Pharmacopoeia.
[0046] The intake amount of the diketopiperazine compound contained in the preventive / ameliorating agent is determined appropriately depending on the age, body weight, sex, symptoms, drug sensitivity, species, etc. of the mammal to be ingested (administered), and is, for example, in the range of 0.1 μg to 200 mg / kg (body weight) / day in terms of the concentration of the diketopiperazine compound. The preventive / ameliorating agent may be ingested once or multiple times (e.g., 2 to 4 times) per day.
[0047] In this specification, examples of "additives" include physiologically acceptable conventional carriers, binders, stabilizers, excipients, diluents, pH buffers, disintegrants, isotonicity agents, coating agents, solubilizers, lubricants, glidants, solubilizers, flavorings, sweeteners, solvents, gelling agents, nutrients, various oils, surfactants, preservatives, antioxidants, dispersants, chelating agents, thickeners, UV absorbers, emulsion stabilizers, pH adjusters, colorants, fragrances, etc. Specific examples of such ingredients include water, physiological saline, animal fats and oils, vegetable oils, lactose, starch, gelatin, crystalline cellulose, gum, talc, magnesium stearate, hydroxypropyl cellulose, polyalkylene glycol, polyvinyl alcohol, glycerin, vitamins, minerals, lactic acid bacteria, protein, and collagen.
[0048] The present preventive / ameliorating agent may contain a component other than the present diketopiperazine compound as a component for preventing or ameliorating the decline in organ function, etc.; however, since the present diketopiperazine compound alone exhibits an excellent inhibitory effect, the agent may not contain any of the above-mentioned components other than the present diketopiperazine compound (e.g., compounds such as proteins, amino acids, DNA, RNA, and polymers; plant-derived extracts [e.g., sesame lignan compounds]).
[0049] The present invention will be explained in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples.
[0050] 1. Confirmation that the Compound Protects Renal and Liver Function in a Renal Failure Model To confirm that the Compound protects renal and liver function in a renal failure model using 2,5-diketopiperazine (cGP; see Table 1), which is included in the Compound, cGP was administered to adenine-fed model mice (hereinafter referred to as "adenine-fed renal failure model mice") that had been induced to develop chronic renal failure, and the blood levels of a uremic substance (creatinine), an indicator of renal function, and the proportion of renal tubules were analyzed, as well as the blood levels of three liver function markers (ALT, AST, and γGTP) and two types of lipids (total cholesterol and TG). The adenine-induced renal failure model mice are mice that develop kidney damage due to the crystallization of ingested adenine as insoluble 2,8-dihydroxyadenine in the renal tubules (Cozzolino, M. et al. Kidney Int. 64, 441-450 (2003); Tamagaki, K. et al. Nephrol. Dial. Transplant 21, 651-659 (2006)).
[0051] 1-1 Method Analysis was performed using adenine-fed renal failure model mice according to the following procedures [1] to [5]. [1] Eight-week-old male C57BL / 6 mice (purchased from Japan CLEA) were divided into a normal-fed group (n = 6) fed a normal diet (CE-2, Japan CLEA) and an adenine-fed group (n = 12) fed a normal diet containing 0.2% adenine (Wako). [2] After 6 weeks of feeding, the adenine-fed group was divided into an adenine-fed control group (n = 6) fed a normal diet and an adenine-fed cGP group (n = 6) fed a normal diet containing cGP. The normal cGP-containing cGP diet was prepared by mixing cGP (Bachem) with the normal diet to a final concentration of 0.0025%. [3] After two weeks of breeding, blood samples were collected from each of the three groups (normally fed group, adenine diet-fed control group, and adenine diet-fed cGP group), and plasma samples (referred to as "plasma samples from the second week after breeding") were prepared according to standard methods. [4] After another week of breeding (a total of three weeks), blood samples were collected from each of the three groups, and plasma samples (referred to as "plasma samples from the third week after breeding") were prepared according to standard methods. Renal tissue was then collected, fixed in 10% neutral buffered formalin, and embedded in paraffin. The paraffin-embedded renal tissue was then sliced to prepare renal tissue sections. [5] Using the "plasma sample from week 2 after feeding," the blood concentration of uremic toxins (creatinine), an indicator of renal function, was measured by mass spectrometry using a liquid chromatograph-tandem mass spectrometer (LC-MS / MS) (Shimadzu Corporation) (see Figure 1). Also, 10 μL of the "plasma sample from week 2 after feeding" and the "plasma sample from week 3 after feeding" were used to measure the blood concentrations of three liver function markers (ALT [see Figure 3A], AST, and γGTP) and two lipids (total cholesterol [see Figure 3B] and TG) using a DRI-CHEM 7000V (Fujifilm Corporation). Furthermore, the prepared kidney tissue sections were analyzed by Masson's trichrome staining (MTS) according to standard methods (see Figure 2).
[0052] 1-2 Results Creatinine concentrations in plasma samples taken two weeks after feeding from the adenine diet control group were significantly higher than those in plasma samples taken two weeks after feeding from the normal-fed group (see Figure 1). Furthermore, the proportion of renal tubules in the adenine diet control group was significantly lower than that in the normal-fed group (see Figure 2A). These results indicate that the blood concentration of a uremic toxin (creatinine) increased in the adenine diet control group (i.e., adenine diet renal failure model mice) due to a decline in renal function associated with renal failure.
[0053] On the other hand, the creatinine concentration in the "plasma sample after two weeks of feeding" of the adenine diet-fed cGP group was shown to be significantly decreased compared to the creatinine concentration in the "plasma sample after two weeks of feeding" of the adenine diet-fed control group (see Figure 1). Furthermore, the proportion of renal tubules in the adenine diet-fed cGP group was shown to be significantly increased compared to the proportion of renal tubules in the adenine diet-fed control group (see Figure 2A). These results indicate that administration of the present compound group (cGP) to adenine diet-fed renal failure model mice improved impaired renal function, resulting in a decrease in the elevated blood concentration of uremic toxins (creatinine). Furthermore, the ALT concentration in the "plasma sample after two weeks of feeding" of the adenine diet-fed cGP group was shown to be significantly decreased compared to the ALT concentration in the "plasma sample after two weeks of feeding" of the adenine diet-fed control group (see Figure 3A). Furthermore, the total cholesterol concentration in the "plasma sample after 2 weeks of feeding" from the adenine diet-fed cGP group was shown to be lower than the total cholesterol concentration in the "plasma sample after 2 weeks of feeding" from the adenine diet-fed control group (see Figure 3B). These results indicate that administration of the present compound group (cGP) to adenine diet-fed renal failure model mice improves liver function and dyslipidemia.
[0054]
[0055] 2. Confirmation that the Compound Protects Renal and Liver Function in a Diabetic Model Next, to confirm that the Compound protects renal and liver function in a diabetic model, cGP was administered to diabetic model mice (db / db mice), and the blood concentrations of two uremic toxins (creatinine and phenyl sulfate) and a factor that leads to renal failure in type 1 diabetic patients (N6-acetyllysine [Ac6Lys]) were analyzed. In addition, the pathological liver tissue and the blood concentrations of three liver function markers (ALT, AST, and γGTP) and two lipids (total cholesterol and TG) were analyzed.
[0056] 2-1 Methods Analysis using diabetic model mice was performed according to the following procedures [1] to [3]. [1] Wild-type mice (BKS-m+ / m+ mice; purchased from Japan CLEA) fed a normal diet (CE-2, manufactured by Japan CLEA) were divided into a wild-type normal-fed group (n = 5) fed on normal diet and a wild-type cGP group (n = 4) fed on normal diet containing cGP. Diabetic model mice (BKS-db / db mice; purchased from Japan CLEA) fed on normal diet were also divided into a diabetic model normal-fed group (n = 4) fed on normal diet and a diabetic model cGP group (n = 4) fed on normal diet containing cGP. Blood samples were collected from the diabetic model cGP group, and plasma samples (referred to as "plasma samples at week 0 after feeding") were prepared according to standard procedures. [2] After 6 weeks of feeding, blood samples were collected from each of the four groups (wild-type, wild-type cGP, diabetic model, and diabetic model cGP). Plasma samples (referred to as "plasma samples at 6 weeks of feeding") were prepared according to standard procedures. Liver tissue was then collected, fixed in 10% neutral buffered formalin, and embedded in paraffin. The paraffin-embedded liver tissue was then sliced to prepare liver tissue sections. [3] Using the "plasma samples at 0 weeks of feeding" and "plasma samples at 6 weeks of feeding," blood concentrations of three substances (creatinine, phenyl sulfate, and Ac6Lys) were measured by mass spectrometry using an LC-MS / MS (Shimadzu Corporation) (see Figures 5 and 6). Additionally, blood concentrations of three liver function markers (ALT, AST, and γGTP) and two lipids (total cholesterol and TG) were also measured. Furthermore, the prepared liver tissue sections were analyzed by hematoxylin-eosin staining (HE) according to a standard method (see FIG. 4).
[0057] 2-2 Results The number of lipid droplets in the liver of the diabetic model cGP group was shown to be reduced compared to that in the liver of the diabetic model normally fed group (see Figure 4). This result indicates that administration of the compound group of the present invention (cGP) to diabetic model mice improves fatty liver.
[0058] Furthermore, the creatinine concentration in the plasma samples from the normally-fed diabetic model group at 6 weeks after feeding was significantly higher than that in the plasma samples from the normally-fed wild-type group and the wild-type cGP group at 6 weeks after feeding (see Figure 5). This result indicates that the blood concentration of a uremic substance (creatinine) increased in the normally-fed diabetic model group as a result of the decline in renal function associated with diabetes.
[0059] On the other hand, the creatinine concentration in the "plasma sample after 6 weeks of feeding" of the diabetic model cGP group was shown to be significantly lower than the creatinine concentration in the "plasma sample after 6 weeks of feeding" of the diabetic model normally fed group (see Figure 5). This result indicates that administration of the compound group of the present invention (cGP) to diabetic model mice improved the impaired renal function, and as a result, the elevated concentration of uremic toxins (creatinine) in the blood was reduced.
[0060] Furthermore, the blood concentrations of three substances (creatinine, phenyl sulfate, and Ac6Lys) were measured using plasma samples from the diabetic model cGP group at week 0 and week 6 after feeding, and the results showed that the blood concentrations of all substances were significantly lower at week 6 after feeding compared to week 0 after feeding (see Figure 6). These results indicate that administration of the compound group (cGP) of the present invention to diabetic model mice improved impaired renal function and reduced the risk of renal failure, resulting in a decrease in the blood concentrations of uremic substances (creatinine and phenyl sulfate) and a decrease in the blood concentration of Ac6Lys, a factor that leads to renal failure in type 1 diabetic patients.
[0061] 3. Confirmation that the present compound reduces chronic inflammation and resulting cell damage in a diabetic model, and prevents vascular complications. Next, to confirm that the present compound reduces chronic inflammation and resulting cell damage in a diabetic model, and prevents vascular complications, cGP was administered to diabetic model mice (db / db mice), and the blood concentrations of two uremic toxins (1-methyladenosine [m1A] and trimethylamine-N-oxide [TMAO]) were analyzed.
[0062] 3-1 Methods Analysis using diabetic model mice was performed according to the following procedures [1] to [3]. [1] Diabetic model mice (BKS-db / db mice; purchased from Japan CLEA) fed a normal diet (CE-2, manufactured by Japan CLEA) were divided into a diabetic model group (n = 10) fed a normal diet and a diabetic model cGP group (n = 10) fed a normal diet containing cGP. [2] After 5 weeks of feeding, blood samples were collected from each of the two groups (the diabetic model group and the diabetic model cGP group), and plasma samples were prepared according to standard methods. [3] Using the prepared plasma samples, the blood concentrations of two uremic toxins (mIA and TMAO) were measured by mass spectrometry using an LC-MS / MS (Shimadzu Corporation) (see Figure 7).
[0063] 3-2 Results The mA concentration in plasma samples from the diabetic model cGP group was significantly reduced compared to the mA concentration in plasma samples from the diabetic model normally fed group (see Figure 7A). Since mA is known to be an early marker that increases during cell damage, administration of the compound group (cGP) to diabetic model mice reduces chronic inflammation and the resulting cell damage.
[0064] Furthermore, the TMAO concentration in the plasma samples from the diabetic model cGP group was shown to be significantly reduced compared to the TMAO concentration in the plasma samples from the diabetic model normally fed group (see Figure 7B). TMAO is known as a factor promoting arteriosclerosis and has been reported to be associated with cardiovascular events and life prognosis. This indicates that administration of the compound group of the present invention (cGP) to diabetic model mice can prevent vascular complications, which are one of the main complications of diabetes.
[0065] The present invention contributes to the prevention and treatment of diseases such as renal failure and diabetes, and to the reduction of the risk of these diseases becoming severe.
Claims
1. An agent for preventing or ameliorating decreased function of an organ or tissue, comprising one or more compounds selected from the group consisting of compounds represented by the following formula (I) and physiologically acceptable salts thereof: [In the formula, R 1 and R 2 each independently represents H or a C1-C6 alkyl group; R 3 and R 4 are each independently H; or a hydroxy group, a phenyl group, a hydroxyphenyl group, or S—CH 3 Group, NH 2 R represents a C1-C6 alkyl group which may have at least one group selected from the group consisting of a carboxy group, a carbamoyl group, a guanidino group, and an N-containing heteroaryl group; 1 and R 3 may form a ring via a C2-C4 alkylene group which may have a hydroxy group, R 2 and R 4 may form a ring via a C2-C4 alkylene group which may have a hydroxy group.] 2. The preventive or ameliorative agent according to claim 1, wherein the compound represented by formula (I) is a compound represented by the following formula (I-1):
3. The preventive or ameliorative agent according to claim 1, wherein the organ is the kidney or liver.
4. The preventive or ameliorating agent according to claim 1, which is used to prevent or ameliorate the decline in organ or tissue function in a mammal suffering from renal failure or diabetes.
5. The preventive or ameliorative agent according to any one of claims 1 to 4, which is a medicine, pet feed, or food or drink.
Citation Information
Patent Citations
Composition for cell protection containing cyclo histidine-proline as active ingredient
JP2021046435A
Glucose metabolism ameliorating agent
WO2015194447A1
Lipase inhibitor
WO2016133157A1
